Two new vaccines
Put to work at the same body to the cells that grow uncontrollably is the strategy that seems to be decanted for cancer research. Two studies presented in 2009 at the Congress of the American Society of Clinical Oncology (ASCO), have shown the effectiveness of separate vaccines to improve the prognosis of two common tumors: non-Hodgkin lymphoma and melanoma.
They are two therapeutic vaccines do not prevent the appearance of the disease but do affect its development and increase the life expectancy of patients. The perspective is stretched over a year in the case of lymphoma and in five months in patients with melanoma, a skin cancer with good prognosis if diagnosed early and bad expectations when it is located and extended.
Although both vaccines are administered in combination with chemotherapy, it was demonstrated that their efficacy opens the door to new clinical trials. The melanoma vaccine is made from a protein in the tumor itself and stimulates the production of T cells, a type of white blood cells multiply and seek out protein gp100 to try to destroy it and with it, the malignant cells.